Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
research and development
Biotech
AZ restarts £300M UK investment, but Merck not budging
AstraZeneca will resume a £300 million investment program in the U.K., seven months after freezing plans in frustration at drug pricing negotiations.
James Waldron
Apr 29, 2026 10:01am
Takeda ends mRNA research pact with Japanese drug discoverer
Apr 14, 2026 9:57am
Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Feb 13, 2026 10:10am
Takeda turns to AI drug designer after whittling down R&D focus
Oct 14, 2025 5:00am
Sanofi inks pact with Canadian tech company to bring AI to R&D
Oct 8, 2025 12:13pm
AZ pauses $271M UK expansion as British backtrack continues
Sep 12, 2025 2:44pm
